Herantis Pharma (HEL: HRTIS)

Last close As at 28/02/2026

EUR2.10

0.00 (0.00%)

Market capitalisation

Herantis Pharma is a Finland-based clinical-stage biotechnology company focused on developing disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases.

Latest Insights

View More

Healthcare | Spotlight — flash

Herantis Pharma — Funding to support HER-096 in Phase II

Healthcare | Spotlight — flash

Herantis Pharma — Biomarker data bolster HER-096 potential

Healthcare | Comment

Herantis Pharma (HEL: HRTIS) – a step closer to Phase II

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Antti Vuolanto

    CEO

  • Tone Kvåle

    CFO

Research

edison tv

Healthcare

Herantis Pharma – executive interview

Spotlight — flash

Healthcare

Herantis Pharma — HER-096 clears Phase Ib, eyes Phase II

Spotlight — update

Healthcare

Herantis Pharma — H125 results reflect Phase Ib progress

Spotlight — flash

Healthcare

Herantis Pharma — Last patient visit completed for Phase Ib

Spotlight — initiation

Healthcare

Herantis Pharma — Dedicated to disease modification for PD

edison tv

Healthcare

Herantis Pharma – executive interview